Integra LifeSciences Launches New Integra(R) CUSA(R) NXT Bone Tip at 2012 Congress of Neurological Surgeons Annual Meeting

Company Logo

PLAINSBORO, N.J., Oct. 9, 2012 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the launch of the Integra® CUSA® NXT Inferior Forward Bone Tip for Integra's CUSA® NXT Ultrasonic Tissue Ablation System. The CUSA® NXT system is a well-recognized medical device used in neurosurgical and other surgical procedures for the controlled and selective removal of soft tissue and bone near critical structures. The Integra® CUSA® NXT Bone Tips have received 510(k) clearance from the United States Food and Drug Administration (FDA), and will be featured at the 2012 Congress of Neurological Surgeons (CNS) annual meeting, October 6 – 10, 2012, in Chicago, Illinois.

The new Integra® CUSA® NXT Inferior Forward Bone Tip expands the surgical applications for the CUSA® NXT system. Driven by the CUSA® Selector® 24kHz Neurosurgical Short handpiece, the Integra® CUSA® NXT Bone Tips allow surgeons to use ultrasonic tissue ablation in procedures requiring precise, controlled bone removal near critical structures where the rotational motion of a drill or frictional heat may be a concern.

The newest tip in the family features a working surface that is oriented towards the inferior (bottom) surface of the tip, making it useful in situations where the surgical setting requires downward pressure for bone removal. "We are excited to expand the tip selection for Integra's CUSA® NXT platform," said Bob Davis, President of Integra's Neurosurgery business. "The orientation of the new tip will help neurosurgeons during cases when they are approaching the bone from above. The tip also generates less heat than competitive devices, which can be very important in certain surgical procedures."

Over 2,000 centers worldwide rely on the CUSA® ultrasonic surgical ablation technology for a variety of procedures, including the removal of tissues associated with brain and abdominal tumors. Integra currently offers a diverse line of CUSA® tissue ablation products, including the CUSA® NXT, CUSA® Excel+, CUSA® Excel, CUSA® Selector®, and CUSA® DissectronTM systems.

Integra LifeSciences, a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedics, neurosurgery, spine, reconstructive and general surgery. For more information, please visit

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use the products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2011 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT: Integra LifeSciences Holdings Corporation Gianna Sabella Director, Corporate Communications (609) 936-2389

Source:Integra LifeSciences Holdings Corp.